Management Team

Adrian Howd has served on the Board since early 2020 and took on the Executive Chairman role in January 2024. He has over 20 years of strategic financial and commercial experience in the biopharmaceutical industry, having led multiple asset and corporate business development transactions, as well as numerous equity capital market fundraises totalling over €430m. He has held various senior roles including Chief Investment Officer and Chief Executive Officer at investment firm, Malin plc, where he led the Company to its debut on the Irish stock exchange in one of the largest European life science initial public offerings to date. At Malin, Dr Howd led investment in and served on the boards of Immunocore and Kymab, two “platform to therapeutic” UK-based companies that both achieved multibillion USD exits. Dr. Howd is currently CFO/CBO at BiVictrix Plc, an Alderley park based Antibody Drug Conjugate (ADC) Therapeutic business.

Juergen Dobmeyer is a seasoned clinical lead and research physician, with considerable experience in drug safety services, regulatory science, experimental and pharmaceutical medicine. He has led all phases of drug development from Proof of Concept through to market support, with a focus on infectious diseases, immunology and oncology. As such, he has supported clinical programmes leading to marketing authorization of novel anti-microbial medications in the US and Europe. Juergen has >20 years of experience as Consultant and Director of Clinical Operations at Galenus GH AG, a therapeutically focused CRO headquartered in Switzerland. He has also held management roles at the Institute for Medical Statics, Frankfurt, and at IMS Health, covering drug safety services, medical affairs, portfolio optimization, forecasting and launch and brand management.

David Cook has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London. David has worked in the pharmaceutical industry for >20 years, predominantly at AstraZeneca in a wide variety of R&D roles both in the UK and the US. He initially worked in the respiratory and inflammation therapy area identifying the mode-of-action for a new class of immunosuppressives. David then moved into the safety functions and led a number of global initiatives developing new approaches to improve the understanding of safety in new medicines. David has experience across the drug discovery and development pipeline from target selection to scientific support in the life cycle of marketed products.

Mark is an experienced finance leader with significant finance and business experience in bioscience, pharmaceutical and other global R&D-led companies. Mark qualified as chartered management accountant in 1999 at BAE Systems and has gone on to spend most of his career in life sciences. He provided the financial leadership to a number of major change projects at AstraZeneca over 8 years, including as Finance Director to its transformational R&D Strategy project. Since leaving AstraZeneca in 2012, he has built organisation capability in a variety of life sciences and healthcare companies as a consultant Finance Director, mainly in the anti-infectives therapy area.